PL2061561T3 - Kompozycje do leczenia raka - Google Patents

Kompozycje do leczenia raka

Info

Publication number
PL2061561T3
PL2061561T3 PL07837326T PL07837326T PL2061561T3 PL 2061561 T3 PL2061561 T3 PL 2061561T3 PL 07837326 T PL07837326 T PL 07837326T PL 07837326 T PL07837326 T PL 07837326T PL 2061561 T3 PL2061561 T3 PL 2061561T3
Authority
PL
Poland
Prior art keywords
compositions
treating cancer
cancer
treating
Prior art date
Application number
PL07837326T
Other languages
English (en)
Inventor
Alan H Auerbach
Arie S Belldegrun
Original Assignee
Janssen Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38916904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2061561(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Oncology Inc filed Critical Janssen Oncology Inc
Publication of PL2061561T3 publication Critical patent/PL2061561T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL07837326T 2006-08-25 2007-08-23 Kompozycje do leczenia raka PL2061561T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92150606P 2006-08-25 2006-08-25
EP07837326.3A EP2061561B1 (en) 2006-08-25 2007-08-23 Compositions for treating cancer
PCT/US2007/018769 WO2008024484A1 (en) 2006-08-25 2007-08-23 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
PL2061561T3 true PL2061561T3 (pl) 2013-12-31

Family

ID=38916904

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07837326T PL2061561T3 (pl) 2006-08-25 2007-08-23 Kompozycje do leczenia raka
PL12160586T PL2478907T3 (pl) 2006-08-25 2007-08-23 Kompozycje do leczenia nowotworu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL12160586T PL2478907T3 (pl) 2006-08-25 2007-08-23 Kompozycje do leczenia nowotworu

Country Status (20)

Country Link
EP (3) EP2478907B1 (pl)
JP (10) JP2010501575A (pl)
KR (4) KR20090059126A (pl)
CN (2) CN104306977A (pl)
AU (6) AU2007287098C1 (pl)
CA (1) CA2661422C (pl)
CY (2) CY1115477T1 (pl)
DK (2) DK2478907T3 (pl)
ES (2) ES2869343T3 (pl)
HR (2) HRP20130961T1 (pl)
HU (1) HUE054495T2 (pl)
IL (3) IL197211A0 (pl)
LT (1) LT2478907T (pl)
NO (2) NO20091190L (pl)
NZ (1) NZ597830A (pl)
PL (2) PL2061561T3 (pl)
PT (2) PT2061561E (pl)
RS (2) RS52956B (pl)
SI (2) SI2478907T1 (pl)
WO (1) WO2008024484A1 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
RS52956B (sr) 2006-08-25 2014-02-28 Janssen Oncology Inc. Kompozicije za tretman kancera
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
AU2008319767B8 (en) * 2007-10-29 2014-01-09 Takeda Pharmaceutical Company Limited Pyrrolo [1,2-C] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
KR20140053836A (ko) 2011-01-11 2014-05-08 글락소스미스클라인 엘엘씨 조합물
RS56759B2 (sr) * 2011-04-01 2024-10-31 Genentech Inc Kombinacija akt inhibitor jedinjenja i abiraterona za upotrebu pri terapeutskim tretiranjima
US20120295932A1 (en) * 2011-05-17 2012-11-22 Western Connecticut Health Network, Inc. Method for the treatment of cancer
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN102336801B (zh) * 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
KR20150017367A (ko) * 2012-06-06 2015-02-16 노파르티스 아게 종양 질환을 치료하기 위한 17-알파-히드록실라제 (c17,20-리아제) 억제제와 특이적 pi-3k 억제제의 조합물
MY180834A (en) 2012-09-26 2020-12-10 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
CN103800296A (zh) * 2012-11-13 2014-05-21 重庆医药工业研究院有限责任公司 一种稳定的阿比特龙口服固体药物组合物及其制备方法
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
KR20180021932A (ko) * 2013-03-15 2018-03-05 아이슈티카 인코포레이티드 아비라테론 아세테이트 제제
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
JP2016515628A (ja) * 2013-04-04 2016-05-30 エグゼリクシス， インコーポレイテッド 癌を治療するための複合薬
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
BR112016006970A2 (pt) * 2013-10-01 2017-08-01 Novartis Ag enzalutamida em combinação com afuresertib para o tratamento de câncer
RU2016116915A (ru) * 2013-10-01 2017-11-13 Новартис Аг Комбинация
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
ES2863500T3 (es) 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
ES3014630T3 (en) 2016-07-29 2025-04-23 Janssen Pharmaceutica Nv Niraparib for use in a method of treating prostate cancer
JOP20190244A1 (ar) * 2017-04-13 2019-10-13 Janssen Pharmaceutica Nv تركيبة علاجية لسرطان البروستاتا
MX2020003845A (es) 2017-10-16 2020-11-06 Aragon Pharmaceuticals Inc Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración.
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
EP3935068B1 (en) 2019-03-06 2023-09-06 Propella Therapeutics, Inc. Abiraterone prodrugs
WO2021031991A1 (zh) * 2019-08-16 2021-02-25 中国科学院分子细胞科学卓越创新中心 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
KR20220166856A (ko) * 2020-04-16 2022-12-19 타반타 테라퓨틱스 헝가리 인코포레이티드 전립선암을 치료하기 위한 방법 및 조성물
CN114560903B (zh) * 2022-03-09 2023-08-01 绍兴市上虞区武汉理工大学高等研究院 一种阿比特龙衍生物的制备方法及其细胞毒性评价
LU506495B1 (en) 2024-03-01 2025-09-01 Alfasan Nederland B V 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
WO1993020097A1 (en) 1992-03-31 1993-10-14 British Technology Group Ltd. 17-substituted steroids useful in cancer treatment
JP2003525254A (ja) * 2000-03-02 2003-08-26 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 併用化学療法
WO2002053138A2 (en) * 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
SI1556058T1 (sl) * 2002-10-23 2008-02-29 Pantarhei Bioscience Bv Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka
US20050054620A1 (en) * 2003-01-13 2005-03-10 Koeffler H. Phillip Paricalcitol as a chemotherapeutic agent
US20060030608A1 (en) * 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
RS52956B (sr) 2006-08-25 2014-02-28 Janssen Oncology Inc. Kompozicije za tretman kancera

Also Published As

Publication number Publication date
JP6740497B2 (ja) 2020-08-12
JP2010501575A (ja) 2010-01-21
SI2061561T1 (sl) 2013-11-29
CN104306977A (zh) 2015-01-28
EP3804730A1 (en) 2021-04-14
NO20200775A1 (no) 2009-03-20
CA2661422C (en) 2017-06-27
AU2015221447B2 (en) 2016-12-15
RS62034B1 (sr) 2021-07-30
EP2478907A2 (en) 2012-07-25
IL227746A0 (en) 2013-09-30
JP6445123B2 (ja) 2018-12-26
JP2012082215A (ja) 2012-04-26
CY1115477T1 (el) 2017-01-04
JP2021038252A (ja) 2021-03-11
AU2007287098B2 (en) 2013-08-15
HK1131577A1 (en) 2010-01-29
DK2478907T3 (da) 2021-05-25
AU2022206696A1 (en) 2022-08-11
PT2478907T (pt) 2021-05-26
EP2478907B1 (en) 2021-04-14
JP2019059750A (ja) 2019-04-18
JP6053279B2 (ja) 2016-12-27
WO2008024484A1 (en) 2008-02-28
IL257681A (en) 2018-04-30
JP2018065859A (ja) 2018-04-26
RS52956B (sr) 2014-02-28
AU2017201764A1 (en) 2017-04-06
PL2478907T3 (pl) 2021-10-25
SI2478907T1 (sl) 2021-08-31
AU2018271331A1 (en) 2018-12-20
NZ597830A (en) 2013-02-22
KR20150108946A (ko) 2015-09-30
AU2007287098C1 (en) 2018-03-15
ES2869343T3 (es) 2021-10-25
CN101528308A (zh) 2009-09-09
EP2061561B1 (en) 2013-07-10
JP2022185091A (ja) 2022-12-13
JP2015110577A (ja) 2015-06-18
CY1124221T1 (el) 2022-05-27
HRP20210670T1 (hr) 2021-06-11
JP2017052791A (ja) 2017-03-16
CA2661422A1 (en) 2008-02-28
EP2478907A3 (en) 2012-08-01
AU2007287098A1 (en) 2008-02-28
AU2015221447A1 (en) 2015-09-17
JP2024164147A (ja) 2024-11-26
HRP20130961T1 (hr) 2013-11-22
JP2020114851A (ja) 2020-07-30
LT2478907T (lt) 2021-06-25
HUE054495T2 (hu) 2021-09-28
KR20200125776A (ko) 2020-11-04
KR20180003636A (ko) 2018-01-09
NO20091190L (no) 2009-03-20
PT2061561E (pt) 2013-10-09
EP2061561A1 (en) 2009-05-27
AU2021201649A1 (en) 2021-04-08
DK2061561T3 (da) 2013-10-07
IL197211A0 (en) 2009-12-24
KR20090059126A (ko) 2009-06-10
AU2015221447B9 (en) 2017-07-20
ES2428634T3 (es) 2013-11-08

Similar Documents

Publication Publication Date Title
PL2478907T3 (pl) Kompozycje do leczenia nowotworu
EP2152722A4 (en) COMPOSITIONS COMPRISING MIR34 THERAPEUTIC AGENTS FOR TREATING CANCER
PL2200431T3 (pl) Nowe kompozycje i metody służące leczeniu raka
IL190882A0 (en) Compositions for cancer therapy
IL197721A0 (en) Compositions and methods for diagnosing and treating cancer
PL2032166T3 (pl) Kompozycje i sposoby diagnozowania i leczenia nowotworów
SI2173379T1 (sl) Sestavki in postopki za zdravljenje in diagnosticiranje raka
IL197914A (en) Antibodies to ereg for cancer treatment
EP2125887A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
ZA201003123B (en) Thiazol derivavtives for treating cancer
EP2155249A4 (en) COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER
IL213398A0 (en) Compounds for treating cancer
IL238394B (en) Preparations containing a combination of factors for the treatment of cancer
SI2187967T1 (sl) Postopki in sestavki za zdravljenje raka
EP2144888A4 (en) METHODS OF TREATING CANCER
EP1979487A4 (en) COBALAMINE COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2099491A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER
EP2174956A4 (en) COMPOSITIONS FOR ANTIFIBRINOLYSIS THERAPY
GB0707556D0 (en) Treatment for cancer
GB0710871D0 (en) Cancer treatment
EP2068629A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
GB0619271D0 (en) Treating cancer
GB0722030D0 (en) Compositions for treating tumours
HUE054409T2 (hu) Új kompozíciók és eljárások rák kezelésére
SI3067054T1 (sl) Novi sestavki in postopki za zdravljenje raka